{"url_path":"/sec/fulc/8-k/2026-06-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-251394-index.html","accession_number":"0001193125-26-251394","cik":"0001680581","ticker":"FULC","issuer_name":"Fulcrum Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-251394-index.html","primary_entity_key":"0001680581","primary_entity_name":"Fulcrum Therapeutics, Inc."},"word_count":66,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn June 1, 2026, Fulcrum Therapeutics, Inc., or the Company, announced the discontinuation of its pociredir program for the treatment of sickle cell disease, or SCD, and the initiation of a comprehensive review of strategic alternatives intended to maximize stockholder value.\n\nA copy of the press release announcing these matters is attached hereto as Exhibit 99.1 and is incorporated herein by reference."}